JPMorgan Chase & Co. Purchases 2,519 Shares of Bio-Rad Laboratories, Inc. $BIO

JPMorgan Chase & Co. raised its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,250 shares of the medical research company’s stock after buying an additional 2,519 shares during the period. JPMorgan Chase & Co.’s holdings in Bio-Rad Laboratories were worth $15,772,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. CIBC Private Wealth Group LLC raised its stake in shares of Bio-Rad Laboratories by 241.2% during the third quarter. CIBC Private Wealth Group LLC now owns 331 shares of the medical research company’s stock valued at $93,000 after acquiring an additional 234 shares during the last quarter. Coldstream Capital Management Inc. bought a new stake in shares of Bio-Rad Laboratories in the third quarter worth about $260,000. CANADA LIFE ASSURANCE Co grew its stake in shares of Bio-Rad Laboratories by 9.7% in the third quarter. CANADA LIFE ASSURANCE Co now owns 14,379 shares of the medical research company’s stock worth $3,884,000 after purchasing an additional 1,270 shares during the last quarter. Verition Fund Management LLC increased its holdings in Bio-Rad Laboratories by 57.2% during the 3rd quarter. Verition Fund Management LLC now owns 6,355 shares of the medical research company’s stock valued at $1,782,000 after purchasing an additional 2,313 shares during the period. Finally, Politan Capital Management LP increased its holdings in Bio-Rad Laboratories by 16.8% during the 3rd quarter. Politan Capital Management LP now owns 3,024 shares of the medical research company’s stock valued at $848,000 after purchasing an additional 436 shares during the period. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 1.1%

NYSE:BIO opened at $276.71 on Friday. The company has a 50-day moving average price of $282.40 and a 200-day moving average price of $298.63. The stock has a market cap of $7.47 billion, a price-to-earnings ratio of 9.91 and a beta of 1.18. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The company had revenue of $693.20 million for the quarter, compared to analysts’ expectations of $694.64 million. During the same quarter in the prior year, the firm earned $2.90 EPS. Bio-Rad Laboratories’s quarterly revenue was up 3.9% compared to the same quarter last year. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Ratings Changes

BIO has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.